417 related articles for article (PubMed ID: 29223431)
1. International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: Results from the GARFIELD-AF, ORBIT-AF I, and ORBIT-AF II registries.
Steinberg BA; Gao H; Shrader P; Pieper K; Thomas L; Camm AJ; Ezekowitz MD; Fonarow GC; Gersh BJ; Goldhaber S; Haas S; Hacke W; Kowey PR; Ansell J; Mahaffey KW; Naccarelli G; Reiffel JA; Turpie A; Verheugt F; Piccini JP; Kakkar A; Peterson ED; Fox KAA; ;
Am Heart J; 2017 Dec; 194():132-140. PubMed ID: 29223431
[TBL] [Abstract][Full Text] [Related]
2. Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation.
Fox KAA; Lucas JE; Pieper KS; Bassand JP; Camm AJ; Fitzmaurice DA; Goldhaber SZ; Goto S; Haas S; Hacke W; Kayani G; Oto A; Mantovani LG; Misselwitz F; Piccini JP; Turpie AGG; Verheugt FWA; Kakkar AK;
BMJ Open; 2017 Dec; 7(12):e017157. PubMed ID: 29273652
[TBL] [Abstract][Full Text] [Related]
3. GARFIELD-AF risk score for mortality, stroke, and bleeding within 2 years in patients with atrial fibrillation.
Fox KAA; Virdone S; Pieper KS; Bassand JP; Camm AJ; Fitzmaurice DA; Goldhaber SZ; Goto S; Haas S; Kayani G; Oto A; Misselwitz F; Piccini JP; Dalgaard F; Turpie AGG; Verheugt FWA; Kakkar AK;
Eur Heart J Qual Care Clin Outcomes; 2022 Mar; 8(2):214-227. PubMed ID: 33892489
[TBL] [Abstract][Full Text] [Related]
4. Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II).
Steinberg BA; Shrader P; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Hylek E; Kowey PR; Mahaffey KW; O'Brien EC; Singer DE; Peterson ED; Piccini JP;
Am Heart J; 2017 Jul; 189():40-47. PubMed ID: 28625380
[TBL] [Abstract][Full Text] [Related]
5. Stroke prevention, 1-year clinical outcomes and healthcare resource utilization in patients with atrial fibrillation in France: Data from the GARFIELD-AF registry.
Le Heuzey JY; Bassand JP; Berneau JB; Cozzolino P; D'Angiolella L; Doucet B; Mantovani LG; Martelet M; Mouallem J; Muller JJ; Pieper K;
Arch Cardiovasc Dis; 2018 Dec; 111(12):749-757. PubMed ID: 29861295
[TBL] [Abstract][Full Text] [Related]
6. Stroke prevention in atrial fibrillation patients in Poland and other European countries: insights from the GARFIELD-AF registry.
Stępińska J; Kremis E; Konopka A; Wożakowska-Kapłon B; Ruszkowski P; Kukla P; Kayani G
Kardiol Pol; 2016; 74(4):362-71. PubMed ID: 26365937
[TBL] [Abstract][Full Text] [Related]
7. Why are outcomes different for registry patients enrolled prospectively and retrospectively? Insights from the global anticoagulant registry in the FIELD-Atrial Fibrillation (GARFIELD-AF).
Fox KAA; Accetta G; Pieper KS; Bassand JP; Camm AJ; Fitzmaurice DA; Kayani G; Kakkar AK;
Eur Heart J Qual Care Clin Outcomes; 2018 Jan; 4(1):27-35. PubMed ID: 28950344
[TBL] [Abstract][Full Text] [Related]
8. Antithrombotic therapy use in patients with atrial fibrillation before the era of non-vitamin K antagonist oral anticoagulants: the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) Phase I cohort.
Huisman MV; Ma CS; Diener HC; Dubner SJ; Halperin JL; Rothman KJ; Teutsch C; Schoof N; Kleine E; Bartels DB; Lip GY;
Europace; 2016 Sep; 18(9):1308-18. PubMed ID: 27335063
[TBL] [Abstract][Full Text] [Related]
9. Risk Profile and 1-Year Outcome of Newly Diagnosed Atrial Fibrillation in Japan - Insights From GARFIELD-AF.
Koretsune Y; Etoh T; Katsuda Y; Suetsugu T; Kumeda K; Sakuma I; Eshima K; Shibuya M; Ando SI; Yokota N; Goto S; Pieper KS; Allu J; Kakkar AK;
Circ J; 2018 Dec; 83(1):67-74. PubMed ID: 30518731
[TBL] [Abstract][Full Text] [Related]
10. Treatment patterns in anticoagulant therapy in patients with newly diagnosed atrial fibrillation in Belgium: results from the GARFIELD-AF registry.
Cools F; Wollaert B; Vervoort G; Verstraete S; Voet J; Hermans K; Heyse A; De Wolf A; Hollanders G; Boussy T; Anné W; Vercammen J; Faes D; Beutels M; Mairesse G; Purnode P; Blankoff I; Vandergoten P; Capiau L; Allu J; Bassand JP; Kayani G;
Acta Cardiol; 2019 Aug; 74(4):309-318. PubMed ID: 30369290
[No Abstract] [Full Text] [Related]
11. Management and 1-Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELD - AF Registry.
Goto S; Angchaisuksiri P; Bassand JP; Camm AJ; Dominguez H; Illingworth L; Gibbs H; Goldhaber SZ; Goto S; Jing ZC; Haas S; Kayani G; Koretsune Y; Lim TW; Oh S; Sawhney JPS; Turpie AGG; van Eickels M; Verheugt FWA; Kakkar AK;
J Am Heart Assoc; 2019 Feb; 8(3):e010510. PubMed ID: 30717616
[TBL] [Abstract][Full Text] [Related]
12. Comparative validation of HAS-BLED, GARFIELD-AF and ORBIT bleeding risk scores in Asian people with atrial fibrillation treated with oral anticoagulant: A report from the COOL-AF registry.
Chichareon P; Winijkul A; Lip GYH; Krittayaphong R
Br J Clin Pharmacol; 2023 Aug; 89(8):2472-2482. PubMed ID: 36942465
[TBL] [Abstract][Full Text] [Related]
13. Temporal trends in antithrombotic treatment of real-world UK patients with newly diagnosed atrial fibrillation: findings from the GARFIELD-AF registry.
Apenteng PN; Gao H; Hobbs FR; Fitzmaurice DA;
BMJ Open; 2018 Jan; 8(1):e018905. PubMed ID: 29331969
[TBL] [Abstract][Full Text] [Related]
14. The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation.
Roldán V; Marín F; Manzano-Fernández S; Gallego P; Vílchez JA; Valdés M; Vicente V; Lip GY
J Am Coll Cardiol; 2013 Dec; 62(23):2199-204. PubMed ID: 24055744
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the CHA
Yao X; Gersh BJ; Sangaralingham LR; Kent DM; Shah ND; Abraham NS; Noseworthy PA
Am J Cardiol; 2017 Nov; 120(9):1549-1556. PubMed ID: 28844514
[TBL] [Abstract][Full Text] [Related]
16. Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry.
Sawhney JP; Kothiwale VA; Bisne V; Durgaprasad R; Jadhav P; Chopda M; Vanajakshamma V; Meena R; Vijayaraghavan G; Chawla K; Allu J; Pieper KS; John Camm A; Kakkar AK;
Indian Heart J; 2018; 70(6):828-835. PubMed ID: 30580852
[TBL] [Abstract][Full Text] [Related]
17. Meta-analysis on performance of ABC and GARFIELD-AF compared to CHA
Ali A; Siddiqui AA; Ali M; Shahid I
Cardiovasc Revasc Med; 2024 Mar; 60():74-81. PubMed ID: 37880043
[TBL] [Abstract][Full Text] [Related]
18. Off-Label Dosing of Non-Vitamin K Antagonist Oral Anticoagulants and Adverse Outcomes: The ORBIT-AF II Registry.
Steinberg BA; Shrader P; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Kowey PR; Mahaffey KW; Naccarelli G; Reiffel J; Singer DE; Peterson ED; Piccini JP;
J Am Coll Cardiol; 2016 Dec; 68(24):2597-2604. PubMed ID: 27978942
[TBL] [Abstract][Full Text] [Related]
19. Impact of oral anticoagulation in patients with atrial fibrillation at very low thromboembolic risk.
Verbrugge FH; Martin AC; Siegal D; Pieper K; Illingworth L; Camm AJ; Fox KAA
Heart; 2020 Jun; 106(11):845-851. PubMed ID: 31806700
[TBL] [Abstract][Full Text] [Related]
20. The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation.
O'Brien EC; Simon DN; Thomas LE; Hylek EM; Gersh BJ; Ansell JE; Kowey PR; Mahaffey KW; Chang P; Fonarow GC; Pencina MJ; Piccini JP; Peterson ED
Eur Heart J; 2015 Dec; 36(46):3258-64. PubMed ID: 26424865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
